The Record header image

Forward to a friend  |  Subscribe  |  The Record Archive  |  Contacts  |  bcbsm.com  |  Print this article

November 2021

Starting Jan. 1, 2022, we’ll change how we cover some drugs

As we’ve let you know before, Blue Cross Blue Shield of Michigan and Blue Care Network want to make sure members receive safe, high-quality care that meets their needs. To accomplish this, we’re making some changes to how we cover some drugs on the Clinical, Custom, Custom Select and Preferred Drug lists, starting Jan. 1, 2022. We’ll send letters to affected members and their groups and providers.

The following is a list of these changes:

Drugs on the Clinical and Custom Drug Lists that won’t be covered

We’ll no longer cover the drugs in the table below. Unless noted, both the brand name and available generic equivalents won’t be covered. If members fill a prescription for one of these drugs on or after Jan. 1, 2022, they’ll be responsible for the full cost.

The drugs that won’t be covered are listed, along with the covered preferred alternatives that have similar effectiveness, quality and safety. When pharmacies fill prescriptions with preferred alternatives, the generic equivalents are dispensed, if available. The example brand names of preferred alternatives are provided for reference. Additional coverage requirements may apply for preferred alternatives, such as prior authorization.

Drugs that won’t be covered Common use or drug class Preferred alternatives
Asmanex®/HFA Asthma Arnuity® Ellipta®, Flovent® HFA/Diskus®, Pulmicort®/Flexhaler, Qvar® Redihaler®
Bevespi® Aerosphere® Chronic obstructive pulmonary disease Anoro® Ellipta®, Stiolto® Respimat®
Dulera® Chronic obstructive pulmonary disease Advair® HFA/Diskus, ® Breo® Ellipta®, Symbicort®
Incruse® Ellipta®, Tudorza® Pressair® Chronic obstructive pulmonary disease Spiriva®/Respimat®
Extavia®, Plegridy® Multiple sclerosis Avonex®, Bafiertam®, Betaseron®, Copaxone®, Kesimpta®, Tecfidera®, Vumerity®
Invokana®, Invokamet®/XR, Qtern®, Steglatro®, Segluromet® Diabetes Farxiga, ® Glyxambi®, Jardiance®, Synjardy XR®, Trijardy XR®, Xigduo XR®
Granix®, Neupogen® Neutropenia Nivestym®, Zarxio®
Oxycontin®, oxycodone ER1 Pain Butrans®, Duragesic®, MS Contin®, Opana ER®, Ultram ER®, Xtampza ER®, Zohydro ER®
Movantik®, Relistor® tablet Constipation Amitiza®, Linzess®, Symproic®
Siliq® Autoimmune conditions (such as plaque psoriasis and psoriatic arthritis) Enbrel®, Humira®, Otezla®, Rinvoq®, Skyrizi®, Stelara®, Tremfya®, Xeljanz®/XR

1Authorized brand alternatives (authorized generics) are drugs that are considered brand-name drugs and don’t have generic equivalents. These drugs are the same as the brand-name drugs but aren’t true generic drugs. The respective brand copayment ill apply for these drugs.

Drugs on Custom Drug List that will have a higher copayment

The following brand-name drugs will have a higher copayment, starting Jan. 1, 2022. We’ve listed each along with the preferred alternatives that have similar effectiveness, quality and safety, but lower copays. When pharmacies fill prescriptions with preferred alternatives, the generic equivalents are dispensed, if available. The example brand names of preferred alternatives are provided for reference. Additional coverage requirements may apply for preferred alternatives, such as prior authorization.

Nonpreferred drugs that will have a higher copayment or won’t be covered for members with a closed prescription drug benefit** Common use or drug class Preferred alternatives
Actemra®, Cimzia®, Taltz® Autoimmune conditions (such as plaque psoriasis and psoriatic arthritis) Enbrel®, Humira®, Otezla®, Rinvoq®, Skyrizi®, Stelara®, Tremfya®, Xeljanz®/XR
Gilenya®, Mayzent®, Rebif® Multiple sclerosis Avonex®, Bafiertam®, Betaseron®, Copaxone®, Kesimpta®, Tecfidera®, Vumerity®
Ajovy® Migraine prevention Aimovig®, Emgality®
Fulphila®, Udenyca®, Ziextenzo® Neutropenia Neulasta®, Nyvepria®
Leukine® Neutropenia Nivestym®, Zarxio®
Nutropin AQ Nuspin® Growth hormone Genotropin®, Norditropin® FlexPro®
Orenitram ER®, Tracleer® suspension, Tyvaso®, Uptravi®, Ventavis® Pulmonary hypertension Adcirca®, Adempas®, Letairis®, Opsumit®, Revatio®, Tracleer® tablet
Viokace® Pancreatic enzyme Creon®, Zenpep®

Drugs on the Custom Select Drug List that won’t be covered

We’ll no longer cover the following brand-name and generic drugs. Unless noted, both the brand name and available generic equivalents won’t be covered. If members fill a prescription for one of these drugs on or after Jan. 1, 2022, they’ll be responsible for the full cost.

The drugs that won’t be covered are listed along with the covered preferred alternatives that have similar effectiveness, quality and safety. When pharmacies fill prescriptions for preferred alternatives, the generic equivalents are dispensed, if available. The example brand names of preferred alternatives are provided for reference. Additional coverage requirements may apply for preferred alternatives, such as prior authorization.

Drugs that won’t be covered Common use or drug class Preferred alternatives
Asmanex®/HFA Asthma Arnuity® Ellipta®, Flovent® HFA/Diskus®, Pulmicort®/Flexhaler, Qvar® Redihaler®
Dulera® Chronic obstructive pulmonary disease Advair® HFA/Diskus, ® Breo® Ellipta®, Symbicort®
Incruse® Ellipta®, Tudorza® Pressair® Chronic obstructive pulmonary disease Spiriva®/Respimat®
Invokana®, Invokamet®/XR, Qtern®, Steglatro®, Segluromet® Diabetes Farxiga, ® Glyxambi®, Jardiance®, Synjardy XR®, Trijardy XR®, Xigduo XR®
Oxycontin®, oxycodone ER1 Pain Butrans®, Duragesic®, MS Contin®, Opana ER®, Ultram ER®, Xtampza ER®, Zohydro ER®
Siliq® Autoimmune conditions (such as plaque psoriasis and psoriatic arthritis) Enbrel®, Humira®, Otezla®, Rinvoq®, Skyrizi®, Stelara®, Tremfya®, Xeljanz®/XR

1Authorized brand alternatives (authorized generics) are drugs that are considered brand-name drugs and don’t have generic equivalents. These drugs are the same as the brand-name drugs but aren’t true generic drugs. The respective brand copayment ill apply for these drugs.

Drugs on the Custom Select Drug List that will have a higher copayment

The following brand-name drugs will have a higher copayment, starting Jan. 1, 2022. We’ve listed each along with the preferred alternatives that have similar effectiveness, quality and safety, but lower copays. When pharmacies fill prescriptions for preferred alternatives, the generic equivalents are dispensed, if available. The example brand names of preferred alternatives are provided for reference. Additional coverage requirements may apply for preferred alternatives, such as prior authorization.

Nonpreferred drugs that will have a higher copayment or won’t be covered for members with a closed prescription drug benefit** Common use or drug class Preferred alternatives
Actemra®, Cimzia®, Taltz® Autoimmune conditions (such as plaque psoriasis and psoriatic arthritis) Enbrel®, Humira®, Otezla®, Rinvoq®, Skyrizi®, Stelara®, Tremfya®, Xeljanz®/XR
Ajovy® Migraine prevention Aimovig®, Emgality®
Fulphila®, Udenyca®, Ziextenzo® Neutropenia Neulasta®, Nyvepria®
Leukine® Neutropenia Nivestym®, Zarxio®
Nutropin AQ Nuspin® Growth hormone Genotropin®, Norditropin® FlexPro®
Orenitram ER®, Tracleer® suspension, Tyvaso®, Uptravi®, Ventavis® Pulmonary hypertension Adcirca®, Adempas®, Letairis®, Opsumit®, Revatio®, Tracleer® tablet

Drugs on the Preferred Drug List that won’t be covered

We’ll no longer cover the following drugs. Unless noted, both the brand name and available generic equivalents won’t be covered. If members fill a prescription for one of these drugs on or after Jan. 1, 2022, they’ll be responsible for the full cost.

The drugs that won’t be covered are listed along with the covered preferred alternatives that have similar effectiveness, quality and safety. When pharmacies fill prescriptions with preferred alternatives, the generic equivalents are dispensed, if available. The example brand names of preferred alternatives are provided for reference. Additional coverage requirements may apply for preferred alternatives, such as prior authorization.

Drugs that won’t be covered Common use or drug class Preferred alternatives
Alvesco®, Asmanex®/HFA, Qvar® Asthma Arnuity® Ellipta®, Flovent® HFA/Diskus®, Pulmicort®/Flexhaler, Qvar® Redihaler®
Bevespi® Aerosphere® Chronic obstructive pulmonary disease Anoro ®Ellipta®, Stiolto® Respimat®
Dulera® Chronic obstructive pulmonary disease Advair® HFA/Diskus®, Breo® Ellipta®, Symbicort®
Incruse® Ellipta® Chronic obstructive pulmonary disease Spiriva®/Respimat®
Extavia®, Plegridy® Multiple Sclerosis Avonex®, Bafiertam®, Betaseron®, Copaxone®, Kesimpta®, Ponvory®, Tecfidera®, Vumerity®
Invokana®, Invokamet®/XR, Segluromet®, Steglatro®, Steglujan® Diabetes Farxiga®, Glyxambi®, Jardiance®, Synjardy XR®, Trijardy XR®, Xigduo XR®
Oxycontin®, oxycodone ER1 Pain Butrans®, Duragesic®, MS Contin®, Opana ER®, Ultram ER®, Xtampza ER®, Zohydro ER®
Relistor® Constipation Linzess®, Movantik®, Symproic®
Siliq® Autoimmune conditions (such as plaque psoriasis and psoriatic arthritis) Enbrel®, Humira®, Otezla®, Rinvoq®, Skyrizi®, Stelara®, Tremfya®, Xeljanz®/XR
Ztlido® Topical anesthetics Lidoderm®

1Authorized brand alternatives (authorized generics) are drugs that are considered brand-name drugs and don’t have generic equivalents. These drugs are the same as the brand-name drugs but aren’t true generic drugs. The respective brand cost share will apply for these drugs.

Drugs on the Preferred Drug List that will have a higher copayment

The following brand-name drugs will have a higher copayment, starting Jan. 1, 2022. We’ve listed each along with the preferred alternatives that have similar effectiveness, quality and safety, but lower copays. When pharmacies fill prescriptions with preferred alternatives, the generic equivalents are dispensed, if available. The example brand names of preferred alternatives are provided for reference. Additional coverage requirements may apply for preferred alternatives, such as prior authorization.

Nonpreferred drugs that will have a higher copayment or won’t be covered for members with a closed prescription drug benefit** Common use or drug class Preferred alternatives
Actemra®, Cimzia®, Taltz® Autoimmune conditions (such as plaque psoriasis and psoriatic arthritis) Enbrel®, Humira®, Otezla®, Rinvoq®, Skyrizi®, Stelara®, Tremfya®, Xeljanz®/XR
Ajovy® Migraine prevention Aimovig®, Emgality®
Aubagio®, Gilenya®, Mayzent®, Rebif®, Zeposia® Multiple sclerosis Avonex®, Bafiertam®, Betaseron®, Copaxone®, Kesimpta®, Ponvory®, Tecfidera®, Vumerity®
Baxdela® Antibiotics Avelox®, Cipro/XR®, Floxin®, Levaquin®
Cayston® Cystic fibrosis Tobi®
Combipatch® Menopause symptoms Activella®, Climara®, Fem-HRT®, Minivelle®, Vagifem®, Vivelle-Dot® 
Daytrana®, Dyanavel XR®, Quillichew ER®, Quillivant XR® Attention deficit hyperactivity disorder Adderall®/XR,*** Aptensio XR®, Concerta®, Focalin®/XR,*** Metadate CD®,*** Methylin®, Mydayis®, Ritalin® LA/SR, Vyvanse®

***Can be opened and sprinkled on applesauce 
Depo-estradiol® Estrogens Climara®, Estrace®, Minivelle®, Vagifem®, Vivelle-Dot®
Diacomit® Anticonvulsants Depakote®, Onfi®, Topamax®
Fetzima® Antidepressants A generic SSRI/SNRI (such as, Celexa®, Cymbalta®, Effexor/XR®, Pristiq®, Prozac®, Zoloft®, etc.), Wellbutrin/SR/XL®
Fragmin® Anticoagulants Lovenox®
Fulphila®, Ziextenzo® Neutropenia Neulasta®, Nyvepria®
Leukine® Neutropenia Nivestym®, Zarxio®
Gelnique® Urinary antispasmodics Detrol/LA®, Ditropan/XL®, Enablex®, Sanctura/XR®, Vesicare®
K-PHOS Original® Potassium replacement Generic potassium replacement products (such as, K-Lor®, Klor-Con packet®, K-Sol®, Potassium Chloride®, K-Tab®)
Latuda® Antipsychotics Abilify®, Clozaril®, Geodon®, Invega®, Risperdal®, Seroquel®/XR, Zyprexa®
Lipofen® Lipid lowering Antara®, Fenoglide®, Lofibra®, Lopid®, Tricor®, Trilipix®
Lupaneta® pack Endometriosis Lupron Depot® 3.75mg, 11.25mg plus Aygestin®
Natesto® Testosterone replacement Androderm®, Androgel®, Android®, Axiron®, Delatestryl®, Depo-Testosterone®, Testim®, Testred®
Novarel® Infertility Cetrotide®, generic ganirelix acetate, Ovidrel®, Pregnyl®
Odactra®, Ragwitek® Allergen-specific immunotherapy Accolate®, Clarinex®, Flonase®, Nasalide®, Nasonex®, over-the-counter Claritin®, over-the-counter Nasacort®, over-the-counter Zyrtec®, Singulair®, Xyzal®
Pancreaze®, Viokace® Pancreatic enzyme Creon®, Zenpep®
Phoslyra® Phosphate binder Phoslo®, Renagel®, Renvela®
Prevymis® Antiviral Valcyte®
Purixan® Immunosuppressant generic mercaptopurine tablets
Rectiv® Miscellaneous gastrointestinal agent Nitro-Bid® ointment
Revlimid® Immunomodulators Thalomid®
Savella® Fibromyalgia Generic SSRI/SNRI (such as, Celexa®, Cymbalta®, Effexor/XR®, Pristiq®, Prozac®, Zoloft®, etc.), generic TCA (Aventyl®, Elavil®, Sinequan®, Tofranil®, etc.), Flexeril®, Neurontin®, Ultram®
Solu-cortef® Corticosteroids Hydrocortisone®, Decadron®, Deltasone®
Talicia® H. pylori infection Prevacid® plus Amoxil® plus Biaxin/XL®; tetracycline plus Flagyl® plus over-the-counter bismuth subsalicylate; Prilosec® plus Amoxil® plus Biaxin/XL®
Tracleer® suspension, Tyvaso®, Uptravi® Pulmonary hypertension Adcirca®, Adempas®, Letairis®, Opsumit®, Revatio®, Tracleer® tablet
Trulance® Constipation Linzess®, Movantik®, Symproic®
Valchlor® Immunosuppressant 8-Mop®, Zolinza®
Varubi® Antiemetic Emend®, Kytril®, Zofran/ODT®
Verquvo Heart conditions Entresto®
Vosevi®, Zepatier® Hepatitis C Epclusa®, Harvoni®
Xifaxan® 200mg Anti-infective Bactrim DS, Vibramycin, Zithromax
Xifaxan® 550mg Miscellaneous gastrointestinal agent

For IBS-D:
Bentyl®, Imodium®, Levbid®, Levsin®, generic SSRI (Celexa®, Paxil®, Zoloft®, etc.), generic TCA (Elavil®, Sinequan®, Tofranil®, etc.)

For hepatic encephalopathy:

lactulose solution
Yupelri® Chronic obstructive pulmonary disease Spiriva®/Respimat®

**A closed prescription drug benefit doesn’t cover non-preferred brand drugs. Only generic and preferred brand drugs are covered.

No portion of this publication may be copied without the express written permission of Blue Cross Blue Shield of Michigan, except that BCBSM participating health care providers may make copies for their personal use. In no event may any portion of this publication be copied or reprinted and used for commercial purposes by any party other than BCBSM.

*CPT copyright 2020 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.